As we look at the diagnostic trends of 2026, the demand for non-invasive testing is driving a surge in the use of surface markers for "liquid biopsies." By detecting specific antigens on circulating tumor cells (CTCs) found in the blood, clinicians can now monitor cancer progression without the need for painful and risky surgical biopsies. The Cell Surface Markers Market is playing a pivotal...